Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

August 27, 2024
Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared HolzEli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities healthcare equity strategist, joins ‘Squawk Box’ to discuss Eli Lilly’s announcement to release single-dose vials of its anti-obesity drug Zepbound, how the news will expand access to the drug, state of the obesity drug market, and more.

Share This

Latest Mizuho News

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

April 20, 2026
Iran war highlights risks in the chemical supply chain

Iran war highlights risks in the chemical supply chain

April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire

Wall Street jumps to near one-month highs after US-Iran ceasefire

April 8, 2026

Mizuho news from around the globe

back-to-top-blue